Renal function is preserved better compared with radical nephrectomy even when tumors are larger than the traditional 4 cm cutoff.
Renal tumors occur at a frequency 7.5 times greater in lithium-treated patients than in the general population, French study shows.
At last follow-up, 41 of 43 patients who underwent partial nephrectomy did not require dialysis.
Patients with levels of 161.5 mg/dL or greater had a 43% decreased risk of death from renal cell carcinoma than those with lower levels.
The finding emerged from a French study of 213 patients with metastatic renal cell carcinoma.
Added to sunitinib, it prolongs progression-free and overall survival in patients with unfavorable-risk metastatic renal cell carcinoma.
The risk of cancer-specific death at 1 year was 48% and 23% for patients whose disease recurred at 3 months and 3 years, respectively.
The proportion of patients undergoing the procedure has stayed at 6%-7% annually.
Larger tumor size, male sex, and higher nephrometry score indicate a greater likelihood that a renal mass is malignant, researchers report.
The DISSRM score may be an easy-to-calculate surrogate for competing risk mortality.
Open procedures, preoperative dialysis, and higher ASA score were significant predictors of readmission after radical nephrectomy.
Patients of lower socioeconomic status present with larger tumors, higher T stage, positive lymph nodes.
Statin use decreases the risk of disease progression after surgery for localized RCC.
Reduced risk of progression of localized renal cell carcinoma observed in patients on statins.
The 5-year disease-free and cancer-specific survival rates were 94.7% and 100%, respectively.
Study shows it can provide durable oncologic control with a low risk of tumor recurrence.
In a small study, researchers show that ultrasound-guided transhepatic radiofrequency ablation is technically feasible.
Increasing health insurance coverage and access to usual source of care necessary to meet targets.
The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Researchers find a 23% increased risk of death among patients who received a transfusion during surgery or post-operative hospitalization.
The estimated recurrence rate at 10 years was 88.3%, data show.
Benefits in cancer-linked symptoms mediated by lower Impact of Event Scale one month after intervention.
Diabetes also found to increase cancer-specific mortality in patients with clear cell renal cell carcinoma.
ACE inhibitors and angiotensin receptor blockers were shown to prolong median overall survival by nine months.
The five-year cancer-specific and overall survival rates were 100% and 97.8%, respectively.
Active smoking shortens progression-free and overall survival, study finds.
Patients with blood group O have a lower risk of lymph node metastases but a higher risk of bilateral disease.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
Patients with this malignancy had a 73% prevalence of simple renal cysts.
Recurrence that occurs more than 48 months after surgery is no longer significantly associated with reduced survival from renal cell carcinoma.